This mattress company is comfy to sleep on, but the IPO price will put YOU in a coma. AVOID at ₹185-195; revisit at ₹120-150.
The Setup: A Success Story That Got Too Full of Itself
It’s 2016. Two young guys named Ankit and Chaitanya realize that India has been sleeping on garbage mattresses for decades (literally—actual garbage-quality innersprings). They decide to disrupt this ₹145 billion market with a simple idea: manufacture mattresses directly, skip the middleman, and sell online with a 100-night free trial.
Plot twist: It works. Spectacularly.
By FY25, Wakefit has grown revenue from ₹81.26 Cr (FY23) to ₹127.37 Cr—a 25% CAGR that would make any growth investor weep with joy. They’ve opened 125 stores, struck deals with 1,500+ multi-brand outlets, and convinced over 1 million Indians that paying ₹5,788 for a memory foam mattress is actually a lifestyle choice, not a financial mistake.
The market agrees.
The problem? The company is barely profitable. PAT margin of 2.80%. Return on invested capital of 4.67%. And the IPO pricing makes Warren Buffett’s head spin at 343x P/E.
Act I: The Operational Excellence (Why We’re Not Shorting This)
Before we get to the valuation disaster, let’s give credit where it’s due: Wakefit’s operational game is next-level.
1. Vertical Integration = Margin Moat
Unlike pure-play D2C competitors (The Sleep Company, Sleepyhead) that outsource manufacturing, or traditional players (Sleepwell, Kurlon) that rely on distributor networks, Wakefit owns the entire value chain.
The Money Shot: This eliminates 20-30% of intermediary costs. Gross margins: 35-40% vs. 15-20% for competitors.
Translation: If a mattress costs Wakefit ₹3,000 to make, Sleepwell needs to spend ₹4,500-5,000 for the same quality. That’s a competitive advantage you can’t fake.
2. Working Capital Management That Makes CFOs Cry (in a Good Way)
Here’s where Wakefit separates itself from mere mortals:
- Working capital days: 4 (FY25) vs. Sheela Foam: 40+ days
- Inventory turnover: 7.73x (i.e., they turn over their stock 8 times a year)
- Cash conversion cycle: Near-zero
What does this mean in human terms? Wakefit takes your money TODAY, makes your mattress TOMORROW, and pays suppliers in 30 days. The company is literally using customer cash to fund growth. Genius.
Sheela Foam? They buy raw materials, sit on inventory for 40 days, then sell. The difference in cash generation is like comparing a Tesla to a 1995 Honda Civic on fuel efficiency.
3. The Omnichannel Play Nobody Else Nailed
- Online dominance: ₹7.2 Cr revenue; 65% from D2C (e-commerce, online reviews, social proof)
- 125 COCO stores: Company-owned retail presence in 62 cities (building brand credibility offline)
- 1,504 MBO outlets: Distribution partnerships without capital intensity
This is NOT just an online brand. This is a fully integrated home furnishings ecosystem.
Why is this a big deal? Because traditional players (Sleepwell) are stuck in dealer networks. New D2C players (The Sleep Company) have no retail presence. Wakefit is the only player threading the omnichannel needle successfully.
Verdict on Operations: 10/10. This company could teach McKinsey consultants about efficient scaling.
Act II: The Profitability Trap (Where Dreams Die)
Now, let’s talk about the elephant in the room: Wakefit is barely profitable, and the IPO is priced as if it’s Amazon.
The PAT Nightmare
| Year | Revenue | Net Profit | Margin | What This Means |
|---|---|---|---|---|
| FY23 | ₹81.26 Cr | -₹14.57 Cr | -17.9% | Burning cash like a teenager with a credit card |
| FY24 | ₹98.64 Cr | -₹1.50 Cr | -1.5% | Almost there… but still bleeding |
| FY25 | ₹127.37 Cr | ₹3.56 Cr | 2.8% | Barely profitable after doubling revenue |
Let’s put this in perspective: A 2.80% PAT margin is below inflation. After all the revenue growth, capex, and operational excellence, Wakefit is making less money per rupee than a government bonds fund.
The Q4 FY25 Collapse
Here’s the smoking gun in the RHP:
- 9M FY25 PAT: ₹9 Cr (positive)
- Full-year FY25 PAT: ₹3.56 Cr (barely positive)
- Implied Q4 PAT: -₹5.44 Cr (LOSS OF ₹45 LAKH PER DAY)
Why the collapse? Store expansion costs. Wakefit opened new COCO stores, paid rent upfront, hired staff, and—wait for it—no revenue yet. Classic IPO red flag: management front-loading costs before proving store unit economics work.
EBITDA Plateau Signals Trouble
| Year | EBITDA | EBITDA Margin |
|---|---|---|
| FY23 | -₹9.6 Cr | -11.8% |
| FY24 | ₹6.58 Cr | 6.67% |
| FY25 | ₹9.08 Cr | 7.13% |
| H1 FY26 | ₹5.16 Cr | 7.13% |
The margins are FLAT. Annualized H1 FY26 EBITDA would be ₹10.3 Cr (same as FY25). Despite 30% YoY revenue growth, EBITDA isn’t scaling proportionally.
Translation: Fixed costs are NOT flexing. Manufacturing overhead, store rent, and employee costs are locked in. Growth isn’t translating to operating leverage.
The Return on Capital Disaster
Wakefit’s ROCE is 4.67% (FY25).
Let that sink in. A growth company is generating 4.67% return on invested capital when the cost of equity (what investors demand) is 12-15%.
The company is destroying shareholder value. Every rupee of capital deployed is worth 67 paise when reinvested in the business (at ROCE 4.67%) but could earn ₹1.15 if put in a diversified index fund.
Act III: The Valuation Insanity
Now we get to the part where the IPO pricing loses all connection with reality.
The Multiples That Make You Go “Huh?”
| Multiple | Wakefit | Sleepwell | Kurlon | What’s Fair? | Wakefit’s Premium |
|---|---|---|---|---|---|
| P/E | 343x | 45-50x | 35-42x | 30-40x | 8.6x PREMIUM |
| EV/EBITDA | 135x | 20-22x | 15-20x | 18-22x | 6.1-7.9x PREMIUM |
| P/B | 24.7x | 2-3x | 2-2.5x | 3-4x | 6-8x PREMIUM |
| Price/Sales | 10.1x | 1.5-2x | 1.8-2.2x | 2-3x | 4-6x PREMIUM |
So Wakefit—which is loss-making, has weak ROCE, and is in a commoditizing industry—trades at 7-8x premium P/E to Sleepwell (profitable, 20% net margins, 40+ years of brand history).
This is like paying 8x more for a brand-new car with an unproven engine than for a Toyota that’s been reliable for 40 years.
The math doesn’t compute.
What Valuation Assumes (Spoiler: It’s Not Happening)
For the 343x P/E to be justified, one of these must occur:
- PAT grows from ₹3.56 Cr to ₹88 Cr (25x) in 3-4 years — requires 70% net margins (vs. current 2.8%)
- Revenue grows 10x while margins stay flat — would require ₹1,274 Cr revenue (10-year horizon, but Wakefit currently at ₹127 Cr)
- Stock price crashes 60-70% to a fair 25x P/E — most likely scenario
The market is pricing Wakefit as if it’s going to become Sleepwell in 5 years. That’s not impossible—but it’s NOT priced in the current ₹343x multiple. You’re paying for perfection without evidence of delivery.
Act IV: The Risk Parade (A Comedy of Errors)
Let’s walk through the risks that keep investment committees up at night:
Risk #1: Growth is Slowing (Quiet Killer)
| Year | YoY Growth |
|---|---|
| FY23→FY24 | 21.4% |
| FY24→FY25 | 29.1% |
| FY25→H1 FY26 | 30% |
It’s flatlined. FY25 to H1 FY26 is basically the same growth rate. Mattress saturation is REAL. Online mattress market is ₹19 Billion (CY24); Wakefit is ₹72 Cr. Even at 50-60% online market share, the TAM is capped.
Furniture is growing faster (50-60% YoY) but starts from a smaller base and requires MORE capital per rupee of revenue. A furniture factory costs ₹100+ Cr. A mattress factory costs ₹30-40 Cr. You do the math.
Risk #2: The Store Expansion Roulette Wheel
Management plans to go from 125 COCO stores to 242 stores. That’s 117 new stores (94% growth).
Problem: No disclosed store-level unit economics. Typical retail store:
- Capex: ₹50-80 lakh per store
- Monthly rental + overhead: ₹5-8 lakh per store
- Breakeven: 18-24 months minimum
- ROI: 8-10% (if it works)
If even 10-15% of stores underperform, the entire expansion thesis unravels. Imagine opening 117 stores and 15 of them are duds—that’s ₹15+ Cr sunk costs and negative store ROIC dragging overall returns.
Risk: We have no idea if this works. The RHP is silent on store economics.
Risk #3: Commoditization & Price Wars
- Sleepwell & Kurlon are cutting prices to defend market share
- The Sleep Company (VC-backed with fresh capital) is aggressive on customer acquisition
- Mattress category is commoditizing — less differentiation, more price competition
Wakefit’s pricing power is eroding. Higher CAC (customer acquisition cost) is showing up in the P&L—advertising spend at ₹96 Cr in FY25 (7.5% of revenue). That’s rising because: (a) Market is crowded, (b) Repeat purchase rate is low (you only buy a mattress every 10 years), (c) Awareness building is expensive.
Risk #4: Free Cash Flow is a Mirage
| Year | OCF | CapEx | FCF |
|---|---|---|---|
| FY25 | ₹76.67 Cr | ₹76.37 Cr | ₹0.30 Cr |
| FY24 | ₹80.59 Cr | ₹78.18 Cr | ₹2.41 Cr |
All operating cash is consumed by CapEx. The company has ZERO organic cash for growth, dividends, or debt repayment. Cash reserves are ₹1.02 Cr (0.33 months of revenue).
One major operational disruption = liquidity crisis.
Risk #5: It’s a VC Exit, Not a Growth Round
Let’s be honest: 70% of the IPO (₹911.71 Cr OFS) is VCs cashing out.
- Peak XV Partners: Selling 20.4 Cr shares
- Verlinvest S.A.: Selling 10.2 Cr shares
- Redwood Trust, Investcorp, SAI Global: All reducing exposure
What does this signal? “We’ve made our returns. Time to exit before things get harder.”
This isn’t Accenture’s IPO where founders say, “We’re going public to accelerate growth!” This is: “We’re going public because we need to give our LPs an exit.”
The Final Word: A Good Company, Terrible Price
Wakefit is a genuinely good business with a genuinely bad IPO valuation.
Think of it like this: Would you buy a Tesla at the price of a Ferrari? That’s what’s happening here.
- At ₹50-80: STEAL (8-10x P/E on normalized earnings)
- At ₹100-130: FAIR VALUE (15-20x P/E on growth assumptions)
- At ₹185-195: INSANE PRICING (343x P/E on current earnings)
What Will Likely Happen:
- IPO Opens: VC-backed hype + retail FOMO drive first-day pop to ₹220-260 (+12-33%)
- Week 2-4: Reality hits. Analysts flag 343x P/E. Stock cracks to ₹140-160 (-28-36% from issue)
- 6-12 Months: If management delivers 15%+ EBITDA margins, stock recovers to ₹180-220. If they don’t, it trades to ₹80-100 (value capitulation)
Bottom Line: AVOID at ₹185-195. Revisit at ₹120-150.
If you believe in Wakefit’s mission to disrupt Indian sleep—great! But don’t overpay for it. This company has proven it can grow and build operations. What it hasn’t proven: it can generate adequate returns on capital and maintain margins as competition intensifies.
Redux: It’s a comfy mattress for the company’s balance sheet, but this IPO price will leave your portfolio sleepless.
P.S. — If it lists at ₹240 and crashes to ₹100 by next year, don’t say we didn’t warn you. Bookmark this page. You’ll want to remind yourself in six months. 😴
This analysis is for educational & entertainment purposes. It’s based on the RHP filed with SEBI (Nov 29, 2025) and public market research. Not financial advice. Consult your advisor. Read the full RHP before investing.
Leave a Reply